Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Incannex Healthcare Ltd ADR(IXHL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IXHL
09/18/2026: IXHL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Incannex Healthcare is a clinical-stage biotechnology company focused on developing proprietary medicinal cannabinoid and psychedelic therapies for conditions like sleep apnea and anxiety. The company’s primary strength lies in its rigorous pursuit of formal regulatory pathways, which sets it apart from more speculative wellness peers. While the potential for high-impact therapeutic breakthroughs creates a compelling long-term opportunity, the firm remains at high risk due to its lack of commercial revenue and the inherent uncertainty of clinical trials. Investors should monitor clinical data readouts and capital management closely, as these are the primary drivers of future value. The stock is best suited for aggressive growth investors capable of managing high-volatility, binary-outcome environments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth play that requires significant patience for clinical trial results. |
| Momentum investor | Strong fit while signal remains positive | The stock can be highly sensitive to positive clinical or regulatory announcements. |
| Value investor | Weak fit | The lack of consistent earnings and high burn rate make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company is in an intensive investment phase with no capacity or intent to pay dividends. |
| Low-risk investor | Weak fit | Extreme volatility and clinical trial risk are incompatible with low-risk objectives. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Speculative nature leads to sharp price fluctuations based on news. |
| Valuation risk | High | Valuation is speculative and tied to unproven future clinical outcomes. |
| Competition risk (Psychedelic/Cannabinoid Pharma) | High | Crowded field increases the risk of other firms getting treatments to market first. |
| Business quality | Medium | While research is rigorous, the business is not yet commercially proven. |
| Dividend income | Low / none | Investors should not expect income. |
| Execution risk | High | Success depends entirely on the outcome of complex FDA clinical trials. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -66.86% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.95M USD | Price to earnings Ratio - | 1Y Target Price 18.12 |
Price to earnings Ratio - | 1Y Target Price 18.12 | ||
Volume (30-day avg) 96.0K shares | Beta 2.83 | 52 Weeks Range 2.49 - 20.31 | Updated Date 09/18/2026 |
52 Weeks Range 2.49 - 20.31 | Updated Date 09/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.7 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Developing and licensing proprietary pharmaceutical formulations. | The company aims to make money by successfully creating and commercializing new FDA-approved drugs. |
Valuation
Trailing PE - | Forward PE 3.78 | Enterprise Value -31.38M | Price to Sales(TTM) 7764.11 |
Enterprise Value -31.38M | Price to Sales(TTM) 7764.11 | ||
Enterprise Value to Revenue 388.53 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 11.96M | Shares Floating 9.60M |
Shares Outstanding 11.96M | Shares Floating 9.60M | ||
Percent Insiders 12.34 | Percent Institutions 3.81 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquarters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 12 | Website https://www.incannex.com |
Full time employees 12 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.